Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2018 / Articles / Mar / No Better Time to Be Humble
Business & Regulation Standards & Regulation Business & Trends

No Better Time to Be Humble

Sitting Down With... Bruno Sepodes, Professor of Pharmacology and Pharmacotherapy, University of Lisbon, Portugal, and Chair of the EMA Committee of Orphan Medicinal Products (COMP).

By Bruno Sepodes 03/14/2018 1 min read

Share

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Bruno Sepodes

Bruno Sepodes is Professor of Pharmacology and Pharmacotherapy, University of Lisbon, Portugal, and Chair of the EMA Committee of Orphan Medicinal Products (COMP).

More Articles by Bruno Sepodes

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Regulators Target Ebola
Standards & Regulation
Regulators Target Ebola

December 1, 2014

0 min read

Will FDA fast review and voucher incentives make a difference?

Safety First - Sizing Up Biologics Side Effects
Standards & Regulation Biosimilars
Safety First - Sizing Up Biologics Side Effects

December 2, 2014

0 min read

Biologic medicines present unique challenges for pharmacovigilance. And with biosimilars hitting the market, life just got more complicated – especially when products share the same name.

United Science Stands
Small Molecules Standards & Regulation
United Science Stands

December 2, 2014

0 min read

Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.